Jane Street Group LLC Cuts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Jane Street Group LLC decreased its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 67.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,736 shares of the biotechnology company's stock after selling 75,644 shares during the period. Jane Street Group LLC owned 0.07% of Astria Therapeutics worth $404,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Astria Therapeutics by 152.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company's stock valued at $3,460,000 after purchasing an additional 189,727 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Astria Therapeutics in the third quarter worth approximately $613,000. FMR LLC grew its stake in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company's stock valued at $86,123,000 after acquiring an additional 1,767,714 shares during the period. Vestal Point Capital LP increased its holdings in shares of Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company's stock valued at $44,040,000 after acquiring an additional 750,000 shares in the last quarter. Finally, Sofinnova Investments Inc. bought a new stake in shares of Astria Therapeutics during the second quarter valued at approximately $552,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

ATXS traded down $0.32 during mid-day trading on Wednesday, reaching $8.35. 201,134 shares of the stock were exchanged, compared to its average volume of 224,167. The company has a 50 day moving average price of $10.06 and a two-hundred day moving average price of $10.72. Astria Therapeutics, Inc. has a 1 year low of $6.91 and a 1 year high of $16.90. The stock has a market capitalization of $471.22 million, a PE ratio of -4.00 and a beta of 0.70.

Wall Street Analysts Forecast Growth

ATXS has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Oppenheimer lifted their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.